Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.71 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6821332 | 1.00 | TDP1 (0.71) | TDP1LMNAALDH1A1L3MBTL1MAPK1 | |
| SCHEMBL31746274 | 1.00 | TDP1 (0.71) | TDP1LMNAALDH1A1L3MBTL1MAPK1 | |
| SCHEMBL21986668 | 0.98 | TDP1 (0.73) | TDP1LMNAALDH1A1L3MBTL1MAPK1 | |
| Hydrochloric Acid SCHEMBL10962809 | 0.97 | TDP1 (0.67) | TDP1LMNAALDH1A1L3MBTL1MAPK1 | |
| SCHEMBL9844077 | 0.93 | TDP1 (0.70) | TDP1LMNAALDH1A1L3MBTL1MAPK1 | |
| SCHEMBL2705481 | 0.90 | TDP1 (0.58) | TDP1LMNAALDH1A1L3MBTL1MAPK1 | |
| SCHEMBL11354710 | 0.88 | TDP1 (0.62) | TDP1LMNAALDH1A1L3MBTL1MAPK1 | |
| SCHEMBL5325886 | 0.87 | ALDH1A1 (0.62) | TDP1LMNAALDH1A1L3MBTL1MAPK1 | |
| SCHEMBL6681556 | 0.87 | TDP1 (0.51) | TDP1LMNAALDH1A1L3MBTL1MAPK1 | |
| SCHEMBL2707155 | 0.87 | TDP1 (0.56) | TDP1LMNAALDH1A1L3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3689849-B1 | PERFUME PRECURSOR | TAKASAGO PERFUMERY CO LTD (JP) | 2025-01-15 | — | — | EP | claimed |
| EP-1248764-A2 | NOVEL METHODS FOR CROSS-METATHESIS OF TERMINAL OLEFINS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2002-10-16 | — | — | EP | claimed |
| US-6414097-B1 | CONTACTING FIRST TERMINAL OLEFIN WITH SECOND DISUBSTITUTED OLEFIN IN PRESENCE OF RUTHENIUM OR OSMIUM CONTAINING CATALYST | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2002-07-02 | — | — | US | claimed |
| WO-2000043343-A2 | NOVEL METHODS FOR CROSS-METATHESIS OF TERMINAL OLEFINS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2000-07-27 | — | — | WO | claimed |
| EP-3689849-B1 | PERFUME PRECURSOR | TAKASAGO PERFUMERY CO LTD (JP) | 2025-01-15 | — | — | EP | disclosed |
| US-11802258-B2 | Perfume precursor | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2023-10-31 | — | — | US | disclosed |
| US-11802258-B2 | Perfume precursor | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2023-10-31 | — | — | US | disclosed |
| US-11802258-B2 | Perfume precursor | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2023-10-31 | — | — | US | disclosed |
| US-20210214644-A1 | PERFUME PRECURSOR | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2021-07-15 | — | — | US | disclosed |
| US-20210214644-A1 | PERFUME PRECURSOR | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2021-07-15 | — | — | US | disclosed |
| EP-3689849-A1 | PERFUME PRECURSOR | Takasago International Corporation (JP) | 2020-08-05 | — | — | EP | disclosed |
| EP-3689849-A1 | PERFUME PRECURSOR | Takasago International Corporation (JP) | 2020-08-05 | — | — | EP | disclosed |
| EP-1180108-B1 | IMIDAZOLIDINE-BASED METAL CARBENE METATHESIS CATALYSTS | CALIFORNIA INST OF TECHN (US) | 2003-08-27 | — | — | EP | disclosed |
| EP-1248764-A2 | NOVEL METHODS FOR CROSS-METATHESIS OF TERMINAL OLEFINS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2002-10-16 | — | — | EP | disclosed |
| US-20020137978-A1 | Synthesis of functionalized and unfunctionalized olefins via cross and ring-closing Metathesis | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-09-26 | — | — | US | disclosed |
| US-6414097-B1 | CONTACTING FIRST TERMINAL OLEFIN WITH SECOND DISUBSTITUTED OLEFIN IN PRESENCE OF RUTHENIUM OR OSMIUM CONTAINING CATALYST | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2002-07-02 | — | — | US | disclosed |
| EP-1180108-A2 | IMIDAZOLIDINE-BASED METAL CARBENE METATHESIS CATALYSTS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2002-02-20 | — | — | EP | disclosed |
| US-6306988-B1 | DIMERIZATION OF OLEFINS IN THE PRESENCE OF RUTHENIUM OR OSMIUM COMPOUND | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2001-10-23 | — | — | US | disclosed |
| WO-2000071554-A2 | IMIDAZOLIDINE-BASED METAL CARBENE METATHESIS CATALYSTS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2000-11-30 | — | — | WO | disclosed |
| WO-2000043343-A2 | NOVEL METHODS FOR CROSS-METATHESIS OF TERMINAL OLEFINS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2000-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11802258-B2 | Perfume precursor | CYP2E1, ADH1A, CYP1A1 | TDP1 3060/4885LMNA 3027/4885ALDH1A1 26/4885 |
| US-20210214644-A1 | PERFUME PRECURSOR | CYP2E1, ADH1A, CYP1A1 | TDP1 3060/4885LMNA 3027/4885ALDH1A1 26/4885 |
| US-20020137978-A1 | Synthesis of functionalized and unfunctionalized olefins via cross and ring-closing Metathesis | OXER1, AOC2, CBR1 | TDP1 4173/4885LMNA 3880/4885ALDH1A1 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.